Short Interest in IN8bio, Inc. (NASDAQ:INAB) Decreases By 51.9%

IN8bio, Inc. (NASDAQ:INAB) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 433,200 shares, a decrease of 51.9% from the January 15th total of 899,800 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average trading volume of 4,110,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INAB. Jane Street Group LLC lifted its holdings in IN8bio by 296.7% in the 4th quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after purchasing an additional 86,696 shares in the last quarter. Geode Capital Management LLC lifted its holdings in IN8bio by 56.5% in the 4th quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after purchasing an additional 185,919 shares in the last quarter. Sigma Planning Corp lifted its holdings in IN8bio by 42.0% in the 3rd quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock valued at $230,000 after purchasing an additional 251,600 shares in the last quarter. Franklin Resources Inc. purchased a new position in IN8bio in the 4th quarter valued at about $1,465,000. Finally, AIGH Capital Management LLC lifted its holdings in shares of IN8bio by 269.7% during the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock worth $1,593,000 after acquiring an additional 4,517,227 shares during the period. 92.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of IN8bio in a research note on Wednesday.

IN8bio Price Performance

NASDAQ:INAB opened at $0.29 on Friday. The firm has a market cap of $21.08 million, a price-to-earnings ratio of -0.39 and a beta of 0.05. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average is $0.28 and its two-hundred day moving average is $0.36. IN8bio has a 12-month low of $0.22 and a 12-month high of $1.74.

IN8bio (NASDAQ:INAB) last released its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Research analysts expect that IN8bio will post -0.56 EPS for the current year.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.